Hormones Clinical Trial
Official title:
CaREFREE Study (Calorie Restriction, Environment and Fitness: Reproductive Effects Evaluation Study)
Verified date | July 28, 2023 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: Functional hypothalamic amenorrhea (functional HA) is a condition where a woman s period stops for a temporary time. This is due to improper function of the hypothalamus. This is the part of the brain that directs the whole reproductive system. Researchers want to learn more about functional HA. They also want to learn how diet, exercise, and other factors may change women s menstrual cycles. Objective: To better understand functional HA. Eligibility: Healthy women ages 18-28 years old who: - Have regular periods - Exercise no more than 4 hours a week - Had their first period at age 11-14 Design: Participants will be prescreened over the phone. Participants will be screened with: - Blood and urine tests - Medical history - Physical exam. Participants will have 9 or 10 visits over about 3 menstrual cycles. These include: - Repeat of screening tests - Questionnaires - Exercise test - Resting energy expenditure test: Participants fast overnight before the test. They lie on their back under a canopy for a half hour. - Body composition test: This is done with a dual energy x-ray absorptiometry (DXA) scan. - Pelvic ultrasound - For two full-day visits, an IV is inserted into an arm vein. The IV takes a blood sample every 10 minutes for 8 hours. Participants will keep logs: - Menstrual cycle log - Diet log for three 4-day cycles Participants will receive test kits to complete at home: - Daily blood and urine sample - Ovulation Participants will take a daily iron supplement. They will wear a wristband that monitors activity 24 hours a day. Participants will stick to a special diet for two 5-day periods of time. They will complete two 4-day exercise programs....
Status | Completed |
Enrollment | 38 |
Est. completion date | June 29, 2019 |
Est. primary completion date | June 29, 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 28 Years |
Eligibility | - INCLUSION CRITERIA: Participants will be enrolled without regard to race or ethnicity. Each potential participant must meet all of the following inclusion criteria in order to be eligible to enroll in the study: 1. Female 2. Between 18 and 28 years of age (inclusive) 3. Reported menarche between the ages of 11 and 14 years 4. Gynecological age of less than or equal to 14 years 5. A history of self-reported regular menstrual cycles when not on contraceptive medication of between 25 and 35 days (inclusive) at prescreen and knowledge of date of onset of menses before the screening visit 6. A BMI of 18.5 to 27 kg (Summation)m(2) and a weight >= 93 lbs. 7. Agrees to use barrier contraception method for the duration of the study and the follow up period 8. Agrees to abstain from alcohol consumption during both 5-day diet/exercise study interventions 9. Agrees to abstain from donating blood during the study and within 30 days of completing the study 10. Agrees to abstain from biotin supplements for the duration of the study 11. Is willing and able to fulfill the requirements of the protocol and to provide informed consent 12. Able to speak and read English 13. Lives within 50 miles of the Clinical Research Unit EXCLUSION CRITERIA: A potential participant meeting any of the following exclusion criteria is not eligible to enroll in the study: 1. Currently lactating or pregnant or planning on becoming pregnant for the duration of the study 2. Has ever given birth 3. History in the past 3 months of dieting or weight loss amounting to greater than 2 kg 4. > 4 hours per week of aerobic exercise for the past 3 months 5. Has initiated training for an athletic sport or event in the past 3 months that, in the opinion of the investigator, may interfere with the results of the study 6. Currently using hormone-based contraception, including those administered orally, vaginally, via injection, sub-dermally, or transdermally 7. Current use of medications or supplements that may interfere with the results of the study, including: i.Steroids ii.Hormone-based contraception iii.Sleeping pills iv.Homeopathic substances (e.g. Chinese herbs, protein or other powders, and other-the-counter extracts) v.Stimulants (e.g. Ritalin) vi.Antidepressants or anti-epileptic medications or centrally acting anti-hypertensive medications 8. Current use of recreational drugs (alcohol intake will be monitored and excluded during the two intervention periods) 9. Unable to consume food containing dairy or nuts 10. Has currently or has a history of any of the following: autoimmune, heart, liver, renal disease, diabetes, or another health condition deemed by the PI to be a contraindication to study participation. History of thyroid disorder is permissible if the patient is biochemically euthyroid on replacement. Additional Eligibility Criteria to be Met Prior to Start of Intervention(s): Criteria 1 Habitual energy intake between 35-55 kcal/kg LBM*day Criteria 2 VO2max less than or equal to 40 ml/kg/min with the option to increase this at the discretion of the PI, depending on the current and past exercise level of the participant. Criteria 3 Hemoglobin, prolactin and TSH within normal female range for testing laboratory. Criteria 4 Ovulation confirmed in the cycle before each study intervention by self-reported positive urine test, ultrasound and/or progesterone blood-levels |
Country | Name | City | State |
---|---|---|---|
United States | NIEHS Clinical Research Unit (CRU) | Research Triangle Park | North Carolina |
Lead Sponsor | Collaborator |
---|---|
National Institute of Environmental Health Sciences (NIEHS) |
United States,
Loucks AB, Thuma JR. Luteinizing hormone pulsatility is disrupted at a threshold of energy availability in regularly menstruating women. J Clin Endocrinol Metab. 2003 Jan;88(1):297-311. doi: 10.1210/jc.2002-020369. — View Citation
Loucks AB. The response of luteinizing hormone pulsatility to 5 days of low energy availability disappears by 14 years of gynecological age. J Clin Endocrinol Metab. 2006 Aug;91(8):3158-64. doi: 10.1210/jc.2006-0570. Epub 2006 May 23. — View Citation
Williams NI, Young JC, McArthur JW, Bullen B, Skrinar GS, Turnbull B. Strenuous exercise with caloric restriction: effect on luteinizing hormone secretion. Med Sci Sports Exerc. 1995 Oct;27(10):1390-8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary outcome measure will be change in daytime LH pulse frequency following 5 days of neutral energy availability as compared to LH pulse frequency following 5 days deficient energy availability. LH pulse frequency. | Change in LH pulse frequency collected by sampling every 10 minutes over 8 hours during a study visit. | NEA Intervention Day 5 and DEA Intervention Day 5 | |
Secondary | Change in hormone measures (LH, FSH, estradiol, and progesterone) from daily urine samples and blood spots, total cycle, follicular and luteal phase length during the cycle following NEA or DEA | Change in Laboratory Values during each menstrual cycle. | Menstrual cycle of the NEA Intervention and menstrual cycle of DEA Intervention | |
Secondary | Change in leptin, ghrelin, adiponectin, insulin, and glucose in response to standardized breakfast, lunch, and snack | Change in Laboratory Values collected by sampling after standardized breakfast, lunch, and snack over 8 hours during a study visit. | NEA Intervention Day 5 and DEA Intervention Day 5 | |
Secondary | Change in cortisol, TSH, TT3, and fT4 | Change in Laboratory Values collected by sampling over 8 hours during a study visit. | NEA Intervention Day 5 and DEA Intervention Day 5 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05022992 -
Effects of a Single Bout of Resistance Training Session on Hormonal Response in Pre-pubertal and Pubertal Boys
|
N/A | |
Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
Completed |
NCT04862208 -
Breakfast Consumption and Energy Balance in Active Adult Males
|
N/A | |
Recruiting |
NCT01121783 -
The Effect of Lactisole on the Responses to Glucose Solution
|
N/A | |
Completed |
NCT03677336 -
Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI
|
Phase 4 | |
Completed |
NCT04414488 -
The Impact of Regional Anaesthesia on Hormone Levels in Thoracic Surgery.
|
||
Completed |
NCT04930224 -
Serum GPER-1 and Oxidant/Antioxidant Levels on Retinopathy in Diabetic Patients
|
||
Completed |
NCT00342498 -
Estrogen Receptor Gene Mutations
|
N/A | |
Completed |
NCT05136742 -
Aerobic Exercise With Diet Induces Hormonal, Metabolic, and Psychological Changes
|
N/A | |
Recruiting |
NCT04326374 -
Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency
|
Phase 3 | |
Completed |
NCT02781727 -
A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
|
Phase 3 | |
Active, not recruiting |
NCT05288166 -
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
|
Phase 3 |